Professor Jeong Nak-gyun of Seoul St. Mary's Hospital Appoints Chairman of the Korean Hematopoietic Cell Transplantation Society
Sep 25, 2025
Professor Jeong Nak-kyun (Department of Pediatric Adolescence) at Seoul St. Mary's Hospital of Catholic University was elected as the chairman of the Korean Hematopoietic Cell Transplantation Society and will serve for two years from September 2025.
Professor Chung graduated from the Catholic University School of Medicine and obtained his master's and doctorate degrees from the same graduate school, and is currently serving as the head professor of the Catholic University School of Medicine's School of Pediatrics and Adolescents. At Seoul St. Mary's Hospital, he served as the clinical director of the Department of Pediatrics and Adolescents, the director of the Medical Ethics Bureau, and the PI director, and has worked hard to treat patients and cultivate their younger students.
In the field of the society, he has served as the policy planning director of the Korean Society of Blood, the general affairs director of the Korean Society of Pediatric Brain Oncology, the general affairs director of the Korean Society of Pediatric Oncology, the education director, and the management director of the division of the Korean Society of Pediatrics. In addition, within the Korean Hematopoietic Cell Transplant Society, he has continuously contributed to the operation and development of the society by serving as the chairman of the transplant registration committee, general affairs director, and financial director.
In the clinical field, more than 1,500 hematopoietic stem cell transplants have been performed on pediatric hematopoietic tumors, and active research results are being made by leading customized treatment strategies for intractable blood diseases. For these contributions, he received the 2022 Korean Society of Pediatric Hematopoietic Oncology Academic Achievement Award and the 2023 Korean Society of Hematopoietic Cell Transplantation Academic Award.
Professor Chung Nak-gyun said, "We will provide the best customized treatment to blood cancer patients and their families, and further strengthen clinical and research capabilities in the domestic hematopoietic stem cell transplantation field."We will do our best to promote the competitiveness of Korea's world-class hematopoietic stem cells through active international academic exchanges and to enhance the global status of the society."
Meanwhile, the Korean Hematopoietic Cell Transplant Society was established in 1991 as the "Korea Bone marrow Transplant Research Society" and has contributed to sharing clinical experience and establishing an institutional foundation in the field of hematopoietic cell transplantation. Since 2017, it has held an international academic conference every year and has established itself as a leading professional society in the field through academic exchanges and research activities at home and abroad.
Professor Chung graduated from the Catholic University School of Medicine and obtained his master's and doctorate degrees from the same graduate school, and is currently serving as the head professor of the Catholic University School of Medicine's School of Pediatrics and Adolescents. At Seoul St. Mary's Hospital, he served as the clinical director of the Department of Pediatrics and Adolescents, the director of the Medical Ethics Bureau, and the PI director, and has worked hard to treat patients and cultivate their younger students.
In the field of the society, he has served as the policy planning director of the Korean Society of Blood, the general affairs director of the Korean Society of Pediatric Brain Oncology, the general affairs director of the Korean Society of Pediatric Oncology, the education director, and the management director of the division of the Korean Society of Pediatrics. In addition, within the Korean Hematopoietic Cell Transplant Society, he has continuously contributed to the operation and development of the society by serving as the chairman of the transplant registration committee, general affairs director, and financial director.
In the clinical field, more than 1,500 hematopoietic stem cell transplants have been performed on pediatric hematopoietic tumors, and active research results are being made by leading customized treatment strategies for intractable blood diseases. For these contributions, he received the 2022 Korean Society of Pediatric Hematopoietic Oncology Academic Achievement Award and the 2023 Korean Society of Hematopoietic Cell Transplantation Academic Award.
Professor Chung Nak-gyun said, "We will provide the best customized treatment to blood cancer patients and their families, and further strengthen clinical and research capabilities in the domestic hematopoietic stem cell transplantation field."We will do our best to promote the competitiveness of Korea's world-class hematopoietic stem cells through active international academic exchanges and to enhance the global status of the society."
Meanwhile, the Korean Hematopoietic Cell Transplant Society was established in 1991 as the "Korea Bone marrow Transplant Research Society" and has contributed to sharing clinical experience and establishing an institutional foundation in the field of hematopoietic cell transplantation. Since 2017, it has held an international academic conference every year and has established itself as a leading professional society in the field through academic exchanges and research activities at home and abroad.
|
This article was translated by Naver AI translator.
